The overall economic return from the Women's Health Initiative estrogen plus progestin trial indicates that the changes in practice it produced provided a net economic return of $37.1 billion over 10 years.
The growth of global spending on oncology medicines has slowed over the past five years, according to a report by the IMS Institute for Healthcare Informatics.
National coverage for low-dose computed tomography may result in more harm than benefit to the Medicare population at this time, said Steven Woolf, a member of the Medicare Evidence Development & Coverage Advisory Committee.
When it appeared that CT screening for lung cancer was a shoo-in for Medicare coverage, the Lung Cancer Alliance, an advocacy group, started to certify “screening centers of excellence.”
Panel: Is It Really Up to LCA to Certify Centers?Moments before the hearing was closed to public comments, guest committee member Michael Gould asked Fenton-Ambrose to describe LCA's certification program for screening centers:
An advisory panel for the Centers for Medicare and Medicaid Services expressed low confidence in low-dose computed tomography as a method for screening for lung cancer in the Medicare population.
Knight's $500 Million GiftDruker has been talking about this approach to diagnostics for at least a decade.
Relying on Staff ScientistsAccording to the paper, laboratories in the U.S. haven't relied on staff scientists, in part because they command higher salaries than trainees and postdocs.
The assumption that growth in research funding would be sustained indefinitely has created an “unsustainable hypercompetitive system” heading toward “long-term decline,” a group of scientists, including NCI Director Harold Varmus, wrote in a paper published in the April 22 edition of the Proceedings of the National Academy of Sciences.
